Log In
Print
BCIQ
Print
Print this Print this
 

TSR-011

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionSmall molecule inhibitor of anaplastic lymphoma kinase (ALK), neurotrophic tyrosine kinase receptor 1 (NTRK1; TrkA), TrkB and TrkC
Molecular Target Anaplastic lymphoma kinase (ALK) ; Neurotrophic tyrosine kinase receptor 1 (TrkA) (NTRK1)
Mechanism of ActionAnaplastic lymphoma kinase (ALK) inhibitor; TrkA antagonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$17.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today